Thyroid Nodular Disease and Thyroid Cancer¶
Chapter 397 | Part 12: Endocrinology and Metabolism
KEY CLINICAL POINTS¶
- Thyroid nodular disease includes goiter, multinodular goiter, and thyroid cancer, with management guided by sonographic evaluation (TI-RADS) and cytology (Bethesda System).
- Amiodarone-induced thyrotoxicosis (AIT) has two types: Type 1 (preexisting thyroid disease) and Type 2 (drug-induced), requiring tailored treatment with radioiodine or surgery.
- Papillary thyroid cancer (PTC) is the most common thyroid cancer, with a favorable prognosis, while anaplastic thyroid cancer (ATC) is aggressive with poor outcomes.
- Radioiodine therapy is central to managing differentiated thyroid cancer, with TSH suppression and ablation protocols to reduce recurrence.
- Thyroid nodules are evaluated using ultrasound, FNA, and molecular testing, with size, sonographic features, and risk stratification guiding management.
1. DEFINITION & OVERVIEW¶
Thyroid nodular disease encompasses benign and malignant conditions, including goiter, multinodular goiter, and thyroid cancer. Thyroid cancer is the most common endocrine malignancy, with differentiated types (e.g., papillary, follicular) having better prognoses than undifferentiated (e.g., anaplastic) variants.
ACR TI-RADS Classification¶
| Composition | EchoGenicity | Shape | Margin | EchoGenic Foci |
|---|---|---|---|---|
| Cystic or almost completely cystic | Anechoic | Wider-than-tall | Smooth | None or large comet-tail artifacts |
| Spongiform | Hyperechoic/isoecho ic/hypoechoic | Taller-than-wide | Irregular | Macrocalcifications |
| Mixed cystic and solid | Very hypoechoic | Lobulated | Extra-thyroidal extension | Punctate echogenic foci |
1.1 Goiter and Thyroid Nodular Disease¶
Goiter refers to thyroid enlargement, often due to iodine deficiency, autoimmune disease, or nodular disease. Thyroid nodules may be benign (e.g., follicular adenoma) or malignant (e.g., papillary carcinoma).
1.2 Thyroid Cancer Classification¶
Thyroid cancer is classified into differentiated (papillary, follicular), poorly differentiated, and anaplastic types. The WHO classification includes developmental abnormalities, follicular cell-derived neoplasms, and C-cell-derived carcinomas (e.g., medullary thyroid cancer).
2. EPIDEMIOLOGY¶
Thyroid nodular disease is common, affecting 3–7% of adults. Iodine deficiency increases goiter prevalence. Thyroid cancer incidence has risen globally, with papillary thyroid cancer (PTC) being the most common subtype. Risk factors include radiation exposure, family history (e.g., MEN 2), and age (>65 years).
2.1 Iodine Deficiency¶
Iodine deficiency causes endemic goiter, with hypothyroidism in 13% of amiodarone-treated patients in iodine-replete regions. Iodine supplementation reduces goiter size.
2.2 Thyroid Cancer Risk Factors¶
Risk factors include childhood radiation exposure, family history (MEN 2, Cowden syndrome), male gender, and age >65 years. MTC is more aggressive in MEN 2B than MEN 2A.
3. ETIOLOGY & PATHOPHYSIOLOGY¶
Thyroid nodules arise from follicular cell hyperplasia, neoplasia, or C-cell tumors. Genetic mutations (e.g., RET/PTC, BRAF V600E) drive malignancy. Amiodarone-induced thyrotoxicosis results from iodine overload and TSH receptor activation.
3.1 Molecular Mechanisms¶
Activating mutations in TSH-R, RET, BRAF, and RAS pathways drive thyroid cancer. Loss of tumor suppressors (e.g., PTEN, P53) and chromosomal abnormalities (e.g., 3p, 11q deletions) are common.
3.2 Amiodarone-Induced Thyrotoxicosis¶
Amiodarone causes thyrotoxicosis via iodine overload, TSH receptor activation, and Wolff-Chaikoff effect. Type 1 AIT is due to preexisting thyroid disease; Type 2 is drug-induced.
4. CLINICAL FEATURES¶
Symptoms of thyroid nodules include neck swelling, dysphagia, and hoarseness. Thyroid cancer may present with painless nodules, lymphadenopathy, or distant metastases. Toxic multinodular goiter (TMNG) causes hyperthyroidism with palpitations and weight loss.
4.1 Goiter Manifestations¶
Diffuse goiter is asymptomatic, while multinodular goiter may cause compressive symptoms (e.g., dyspnea, stridor). Toxic nodules present with hyperthyroidism.
4.2 Thyroid Cancer Symptoms¶
Painless nodules, cervical lymphadenopathy, or distant metastases (e.g., bone, lung) are common. Anaplastic thyroid cancer presents with rapid growth and local invasion.
5. DIFFERENTIAL DIAGNOSIS¶
Differential diagnoses include Graves' disease, Hashimoto's thyroiditis, and thyroiditis. For nodules, consider benign (adenoma) vs. malignant (carcinoma) lesions, and exclude other causes of hyperthyroidism (e.g., TSH-secreting tumors).
5.1 Hyperthyroidism¶
Differentiate between Graves' disease (autoimmune), toxic nodules, and TSH-secreting tumors. Thyroid scan helps identify
6. INVESTIGATIONS & DIAGNOSIS¶
Thyroid function tests (TSH, FT4) and ultrasound are initial investigations. Radioiodine uptake, fine-needle aspiration (FNA), and molecular testing (e.g., BRAF, RET/PTC) aid diagnosis. TI-RADS and Bethesda systems guide management.
Bethesda System for Thyroid Cytology¶
| Diagnostic Category | Risk of Malignancy |
|---|---|
| I. Nondiagnostic or unsatisfactory | 13% (5–20%) |
| II. Benign | 4% (2–7%) |
| III. Atypia of unknown significance (AUS) | 22% (13–30%) |
| IV. Follicular neoplasm (FN) | 30% (23–34%) |
| V. Suspicious for malignancy (SFM) | 74% (67–83%) |
| VI. Malignant | 97% (97–100%) |
7. MANAGEMENT & TREATMENT¶
Management depends on nodule type and malignancy risk. Benign nodules may be observed, while malignant tumors require surgery, radioiodine, or targeted therapy. TSH suppression and ablation protocols are critical for thyroid cancer.
8. PROGNOSIS & COMPLICATIONS¶
Differentiated thyroid cancer has a favorable prognosis with early detection, while anaplastic thyroid cancer is aggressive with poor survival. Complications include hypothyroidism, thyrotoxicosis, and recurrent laryngeal nerve injury from surgery.
9. SPECIAL CONSIDERATIONS¶
Pregnancy requires careful management of thyroid dysfunction, with levothyroxine adjustment. Pediatric patients may have familial thyroid cancer (e.g., MEN 2). Elderly patients require cautious TSH suppression to avoid atrial fibrillation.
10. KEY POINTS & CLINICAL PEARLS¶
Thyroid nodules are evaluated using ultrasound (TI-RADS) and FNA (Bethesda System). Radioiodine ablation is central to managing differentiated thyroid cancer. Amiodarone-induced thyrotoxicosis requires TSH suppression and careful monitoring. Molecular testing improves diagnosis of indeterminate nodules.